PF-Atlas › Clinical Trials › NCT03597347

Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

Molgramostim nebulizer solution · Phase 2

Registry ID
NCT03597347
Phase
Phase 2
Status
Terminated
Drug / intervention
Molgramostim nebulizer solution
Sponsor
Savara Inc.
Start
2019-06-20
Enrollment
14
Locations
5

About this trial

A study to evaluate the efficacy of inhaled molgramostim administered open-label to adult cystic fibrosis (CF) subjects with chronic pulmonary nontuberculous mycobacterial (NTM) infection, with or without ongoing antimycobacterial guideline based combination therapy.

View NCT03597347 on ClinicalTrials.gov →

Explore related

All Molgramostim nebulizer solution trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03597347 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.